Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

Jacob A Gordon; Carlo Buonerba; Gregory Pond; Daniel Crona; Silke Gillessen; Giuseppe Lucarelli; Sabrina Rossetti; Tanya Dorff; Salvatore Artale; Jennifer A Locke; Davide Bosso; Matthew Ivan Milowsky; Mira Sofie Witek; Michele Battaglia; Sandro Pignata; Cyrus Cherhroudi; Michael E Cox; Pietro De Placido; Dario Ribera; Aurelius Omlin; Gaetano Buonocore; Kim Chi; Christian Kollmannsberger; Daniel Khalaf; Gaetano Facchini; Guru Sonpavde; Sabino De Placido; Bernhard J Eigl; Giuseppe Di Lorenzo

doi:10.18632/oncotarget.24888

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

Jacob A Gordon, Carlo Buonerba, Gregory Pond, Daniel Crona, Silke Gillessen, Giuseppe Lucarelli, Sabrina Rossetti, Tanya Dorff, Salvatore Artale, Jennifer A Locke, Davide Bosso, Matthew Ivan Milowsky, Mira Sofie Witek, Michele Battaglia, Sandro Pignata, Cyrus Cherhroudi, Michael E Cox, Pietro De Placido, Dario Ribera, Aurelius OmlinGaetano Buonocore, Kim Chi, Christian Kollmannsberger, Daniel Khalaf, Gaetano Facchini, Guru Sonpavde, Sabino De Placido, Bernhard J Eigl, Giuseppe Di Lorenzo

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

90 Downloads (Pure)

Abstract

Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide.

Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated. The associations of statins with early (≤12 weeks) prostate-specific antigen (PSA) declines (> 30%), cancer-specific survival and overall survival (OS) were evaluated after controlling for known prognostic factors.

Results: Five hundred and ninety-eight patients treated with second-line abiraterone or enzalutamide after docetaxel for mCRPC were included. A total of 199 men (33.3%) received statins during abiraterone/enzalutamide treatment. Median OS was 20.8 months (95% CI = 18.3-23.2) for patients who received statins, versus 12.9 months (95% CI = 11.4-14.6) for patients who did not receive statins (P < 0.001). After adjusting for age, alkaline phosphatase, PSA, neutrophil-to-lymphocytes ratio, Charlson comorbidity score, Gleason score, visceral disease, hemoglobin, opiate use and abiraterone versus enzalutamide treatment, the use of statin therapy was associated with a 53% reduction in the overall risk of death (hazard ratio [HR] = 0.47; 95% CI = 0.35-0.63; P < 0.001). Statin use was also associated with a 63% increased odds of a > 30% PSA decline within the first 12 weeks of treatment (OR = 1.63; 95% CI = 1.03-2.60; P = 0.039).

Conclusions: In this retrospective cohort, statin use was significantly associated with both prolonged OS and cancer-specific survival and increased early > 30% PSA declines. Prospective validation is warranted.

Original language	English
Pages (from-to)	19861-19873
Number of pages	13
Journal	Oncotarget
Volume	9
Issue number	28
DOIs	https://doi.org/10.18632/oncotarget.24888
Publication status	Published - 13 Apr 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.24888Licence: CC BY

24888-347604-4-PBFinal published version, 1.25 MBLicence: CC BY

Fingerprint

Dive into the research topics of 'Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study'. Together they form a unique fingerprint.

Cite this

Gordon, J. A., Buonerba, C., Pond, G., Crona, D., Gillessen, S., Lucarelli, G., Rossetti, S., Dorff, T., Artale, S., Locke, J. A., Bosso, D., Milowsky, M. I., Witek, M. S., Battaglia, M., Pignata, S., Cherhroudi, C., Cox, M. E., De Placido, P., Ribera, D., ... Di Lorenzo, G. (2018). Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 9(28), 19861-19873. https://doi.org/10.18632/oncotarget.24888

@article{8320e911ea804ee59f076f1f6c7664a4,

title = "Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study",

abstract = "Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide.Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated. The associations of statins with early (≤12 weeks) prostate-specific antigen (PSA) declines (> 30%), cancer-specific survival and overall survival (OS) were evaluated after controlling for known prognostic factors.Results: Five hundred and ninety-eight patients treated with second-line abiraterone or enzalutamide after docetaxel for mCRPC were included. A total of 199 men (33.3%) received statins during abiraterone/enzalutamide treatment. Median OS was 20.8 months (95% CI = 18.3-23.2) for patients who received statins, versus 12.9 months (95% CI = 11.4-14.6) for patients who did not receive statins (P < 0.001). After adjusting for age, alkaline phosphatase, PSA, neutrophil-to-lymphocytes ratio, Charlson comorbidity score, Gleason score, visceral disease, hemoglobin, opiate use and abiraterone versus enzalutamide treatment, the use of statin therapy was associated with a 53% reduction in the overall risk of death (hazard ratio [HR] = 0.47; 95% CI = 0.35-0.63; P < 0.001). Statin use was also associated with a 63% increased odds of a > 30% PSA decline within the first 12 weeks of treatment (OR = 1.63; 95% CI = 1.03-2.60; P = 0.039).Conclusions: In this retrospective cohort, statin use was significantly associated with both prolonged OS and cancer-specific survival and increased early > 30% PSA declines. Prospective validation is warranted.",

author = "Gordon, {Jacob A} and Carlo Buonerba and Gregory Pond and Daniel Crona and Silke Gillessen and Giuseppe Lucarelli and Sabrina Rossetti and Tanya Dorff and Salvatore Artale and Locke, {Jennifer A} and Davide Bosso and Milowsky, {Matthew Ivan} and Witek, {Mira Sofie} and Michele Battaglia and Sandro Pignata and Cyrus Cherhroudi and Cox, {Michael E} and {De Placido}, Pietro and Dario Ribera and Aurelius Omlin and Gaetano Buonocore and Kim Chi and Christian Kollmannsberger and Daniel Khalaf and Gaetano Facchini and Guru Sonpavde and {De Placido}, Sabino and Eigl, {Bernhard J} and {Di Lorenzo}, Giuseppe",

year = "2018",

month = apr,

day = "13",

doi = "10.18632/oncotarget.24888",

language = "English",

volume = "9",

pages = "19861--19873",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "28",

}

Gordon, JA, Buonerba, C, Pond, G, Crona, D, Gillessen, S, Lucarelli, G, Rossetti, S, Dorff, T, Artale, S, Locke, JA, Bosso, D, Milowsky, MI, Witek, MS, Battaglia, M, Pignata, S, Cherhroudi, C, Cox, ME, De Placido, P, Ribera, D, Omlin, A, Buonocore, G, Chi, K, Kollmannsberger, C, Khalaf, D, Facchini, G, Sonpavde, G, De Placido, S, Eigl, BJ & Di Lorenzo, G 2018, 'Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study', Oncotarget, vol. 9, no. 28, pp. 19861-19873. https://doi.org/10.18632/oncotarget.24888

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. / Gordon, Jacob A; Buonerba, Carlo; Pond, Gregory et al.
In: Oncotarget, Vol. 9, No. 28, 13.04.2018, p. 19861-19873.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure

T2 - the international retrospective observational STABEN study

AU - Gordon, Jacob A

AU - Buonerba, Carlo

AU - Pond, Gregory

AU - Crona, Daniel

AU - Gillessen, Silke

AU - Lucarelli, Giuseppe

AU - Rossetti, Sabrina

AU - Dorff, Tanya

AU - Artale, Salvatore

AU - Locke, Jennifer A

AU - Bosso, Davide

AU - Milowsky, Matthew Ivan

AU - Witek, Mira Sofie

AU - Battaglia, Michele

AU - Pignata, Sandro

AU - Cherhroudi, Cyrus

AU - Cox, Michael E

AU - De Placido, Pietro

AU - Ribera, Dario

AU - Omlin, Aurelius

AU - Buonocore, Gaetano

AU - Chi, Kim

AU - Kollmannsberger, Christian

AU - Khalaf, Daniel

AU - Facchini, Gaetano

AU - Sonpavde, Guru

AU - De Placido, Sabino

AU - Eigl, Bernhard J

AU - Di Lorenzo, Giuseppe

PY - 2018/4/13

Y1 - 2018/4/13

N2 - Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide.Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated. The associations of statins with early (≤12 weeks) prostate-specific antigen (PSA) declines (> 30%), cancer-specific survival and overall survival (OS) were evaluated after controlling for known prognostic factors.Results: Five hundred and ninety-eight patients treated with second-line abiraterone or enzalutamide after docetaxel for mCRPC were included. A total of 199 men (33.3%) received statins during abiraterone/enzalutamide treatment. Median OS was 20.8 months (95% CI = 18.3-23.2) for patients who received statins, versus 12.9 months (95% CI = 11.4-14.6) for patients who did not receive statins (P < 0.001). After adjusting for age, alkaline phosphatase, PSA, neutrophil-to-lymphocytes ratio, Charlson comorbidity score, Gleason score, visceral disease, hemoglobin, opiate use and abiraterone versus enzalutamide treatment, the use of statin therapy was associated with a 53% reduction in the overall risk of death (hazard ratio [HR] = 0.47; 95% CI = 0.35-0.63; P < 0.001). Statin use was also associated with a 63% increased odds of a > 30% PSA decline within the first 12 weeks of treatment (OR = 1.63; 95% CI = 1.03-2.60; P = 0.039).Conclusions: In this retrospective cohort, statin use was significantly associated with both prolonged OS and cancer-specific survival and increased early > 30% PSA declines. Prospective validation is warranted.

AB - Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide.Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated. The associations of statins with early (≤12 weeks) prostate-specific antigen (PSA) declines (> 30%), cancer-specific survival and overall survival (OS) were evaluated after controlling for known prognostic factors.Results: Five hundred and ninety-eight patients treated with second-line abiraterone or enzalutamide after docetaxel for mCRPC were included. A total of 199 men (33.3%) received statins during abiraterone/enzalutamide treatment. Median OS was 20.8 months (95% CI = 18.3-23.2) for patients who received statins, versus 12.9 months (95% CI = 11.4-14.6) for patients who did not receive statins (P < 0.001). After adjusting for age, alkaline phosphatase, PSA, neutrophil-to-lymphocytes ratio, Charlson comorbidity score, Gleason score, visceral disease, hemoglobin, opiate use and abiraterone versus enzalutamide treatment, the use of statin therapy was associated with a 53% reduction in the overall risk of death (hazard ratio [HR] = 0.47; 95% CI = 0.35-0.63; P < 0.001). Statin use was also associated with a 63% increased odds of a > 30% PSA decline within the first 12 weeks of treatment (OR = 1.63; 95% CI = 1.03-2.60; P = 0.039).Conclusions: In this retrospective cohort, statin use was significantly associated with both prolonged OS and cancer-specific survival and increased early > 30% PSA declines. Prospective validation is warranted.

U2 - 10.18632/oncotarget.24888

DO - 10.18632/oncotarget.24888

M3 - Article

C2 - 29731989

SN - 1949-2553

VL - 9

SP - 19861

EP - 19873

JO - Oncotarget

JF - Oncotarget

IS - 28

ER -